The economics of personalised medicine in low and middle income countries
14 Dec 2017
The economics of personalised medicine in low and middle income countries
Creating a culture of shared data
Accelerating research to the bedside
Developing drugs for personalised medicine
The Innovative Medicines Initiative
Lenalidomide with rituximab for mantle cell lymphoma
Results of the AML 12 trial
Why we are not ready for personalised medicine
Genetically profiling entire populations, starting with Estonia
How does ancestry affect your health?
Neuroblastoma and cell communication networks
Personalised medicine differs from precision medicine